Baseline characteristics of FLDMD, SLDMD and placebo arms.

<p>Baseline characteristics of FLDMD, SLDMD and placebo arms.</p

Association between SES and access to a second-line DMT for RRMS patients after a 5-years delay between first and second line DMT.

<p>Association between SES and access to a second-line DMT for RRMS patients after a 5-years delay between first and second line DMT.</p

Flow chart of systematic review.

<p>*One study could be included at 12 and 24 months. DMD: Disease Modifying Drug; FLDMD: First-line DMD; SLDMD: Second-line DMD; PCB: Placebo; BPF: Brain Parenchymal Fraction; SIENA: Structural Image Evaluation, using Normalisation, of Atrophy.</p

Primary characteristics of the 35 included studies.

<p>Primary characteristics of the 35 included studies.</p

Characteristics of patients diagnosed with RRMS during the period [1982–2011] in Western-Normandy.

<p>Characteristics of patients diagnosed with RRMS during the period [1982–2011] in Western-Normandy.</p

Association between SES and access to a second-line DMT for RRMS patients.

<p>Association between SES and access to a second-line DMT for RRMS patients.</p

Flow chart of population of interest extracted from the Western-Normandy MS network database (n = 733).

<p>DMT: Disease Modifying Treatment. SPMS: Secondary Progressive Multiple Sclerosis. RRMS: Relapsing Remitting Multiple Sclerosis.</p

Additional file 1: of Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial

SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOCX 49 kb

Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier

Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrie

Comparison of the survival in MS patients with the survival of the French general population.

<p>Kaplan-Meier survival estimates according to time from MS clinical onset (years). MS = Multiple Sclerosis.</p